Core Insights - PayPoint Plc and International Distribution Services (IDS) have announced a strategic investment in Collect+, acquiring a 49% stake for £43.9 million, valuing Collect+ at £90 million [2][4] - The partnership aims to enhance Collect+'s growth and position as a leading out-of-home (OOH) store network in the UK, with plans to upgrade 500 sites to offer Royal Mail services and expand further over the next year [3][4] Financial Implications - PayPoint will propose a special dividend of 50.0 pence per share and a share consolidation of 12 for 13, subject to shareholder approval at a Special General Meeting on 17 October 2025 [5][11] - The transaction is expected to enhance earnings per share (EPS) in the first full year to March 2027, driven by the special dividend, share consolidation, and anticipated growth in Royal Mail service volumes through the Collect+ network [5][12] Operational Developments - Collect+ currently operates over 14,000 OOH locations in the UK, with nearly 8,000 offering Royal Mail services, and plans to roll out Royal Mail Shop branding across these sites starting in October [3][4] - The introduction of Royal Mail over-the-counter services and self-service kiosks is expected to improve customer convenience and expand service offerings [6][7] Shareholder Returns - The total return to shareholders for the current financial year is projected to exceed £90 million, combining the special dividend, ordinary dividend, and ongoing share buyback [6][8] - The special dividend is contingent upon shareholder approval and is expected to be paid on 31 October 2025, following the completion of the share consolidation [13][14]

Core Viewpoint - Morgan Stanley's recent report on Vale (VALE.US) highlights discussions with CFO Marcelo Bacci regarding shareholder returns, railway operations, iron ore product flexibility, copper business growth strategies, and challenges in the nickel segment [1][2]. Group 1: Financial Strategies and Shareholder Returns - The company may distribute a special dividend if net debt falls below $15 billion, with expectations for this to occur by December 2025 if iron ore prices remain high and operations are stable [2][3]. - Management is optimistic about the Brazilian railway concession, despite previous unsuccessful negotiations with the government, and is focused on maintaining control over railway assets until 2057 [2][3]. Group 2: Market Outlook and Product Strategy - The iron ore market is expected to tighten by 2026, with prices projected to remain above $90 per ton, prompting Vale to invest in a flexible product portfolio with an annual capacity of 360 million tons [2][3]. - The company plans to focus on supplying high-silica iron ore to the Chinese market and introducing new mid-grade products, which could generate additional revenue [3]. Group 3: Copper and Nickel Business Developments - The copper business aims to increase production to 700,000 tons per year, primarily relying on internal resources rather than acquisitions, with the Manara project aligning with this growth strategy [3]. - Although the nickel segment has seen cost reductions, it has not yet reached breakeven, and there are no plans for expansion in Canada, with a preference for developing multi-metal mines instead [3].

Core Viewpoint - Green Heart Group (00094.HK) announced a conditional sale agreement for assets worth NZD 134 million (approximately HKD 615 million) and plans to distribute a special dividend of HKD 0.01 per share, pending shareholder approval [1][2] Group 1: Sale Agreement Details - The sale agreement involves the sale of assets by the sellers, which are indirect wholly-owned subsidiaries of the company, to a buyer registered in New Zealand [1] - The assets include approximately 12,724 hectares of land in the Mangakahia Forest, along with buildings, trees, and other improvements, as well as carbon units and operational data related to the properties [2] - The buyer's ultimate beneficial owner is Stichting INGKA Foundation, a Dutch charity founded by Ingvar Kamprad [1] Group 2: Asset Description - Seller One will sell land in the Northland region, while Seller Two will sell land in the Gisborne region, both including trees and other improvements [2] - The assets also include all records and operational data related to the trees and properties [2] - Trading of the company's shares was suspended on September 1, 2025, and an application for resumption of trading was submitted for September 11, 2025 [2]

Core Viewpoint - RIMBACO (1953.HK) experienced a significant intraday increase of 107.69%, reaching a new high of 0.27 HKD since December 2022, despite low trading volume of less than 4 million HKD [1] Summary by Relevant Sections - **Stock Performance** - The stock price of RIMBACO surged by 107.69% to 0.27 HKD, marking the highest level since December 2022 [1] - Trading volume remained low, with less than 4 million HKD transacted [1] - **Dividend Announcement** - The company declared a special dividend of 3.7 HKD cents per share [1] - This special dividend is scheduled to be paid on September 15, 2023, to shareholders listed as of the close of business on September 4, 2023 [1]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has applied for the listing and trading of 112.7 million H-shares on the Hong Kong Stock Exchange, based on the assumption that all shareholders will convert their shares according to the exchange ratio and merger agreement [1][2] Group 1 - The company plans to privatize Dongyang Sunshine Changjiang Pharmaceutical by issuing H-shares as consideration to acquire the H-shares held by shareholders, with a conversion ratio of 0.263614 new H-shares for each H-share of Dongyang Sunshine Changjiang Pharmaceutical [2] - A special dividend of HKD 1.50 per share will be paid to shareholders of Dongyang Sunshine Changjiang Pharmaceutical, who collectively hold approximately 427.6 million shares, upon the completion of the privatization [2] - Upon completion of the privatization, Dongyang Sunshine Changjiang Pharmaceutical's listing status on the exchange will be revoked, and the company will assume all assets, liabilities, and rights of Dongyang Sunshine Changjiang Pharmaceutical [2] Group 2 - The H-shares will be eligible securities for Hong Kong clearing once approved for listing and trading, allowing for deposit, settlement, and transfer in the central clearing system [3]